Patents Issued in February 7, 2019
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRESBYOPIA
    Publication number: 20190038609
    Abstract: The invention provides compositions and methods for the treatment of presbyopia. The compositions preferably comprise aceclidine and a cryoprotectant. The compositions optionally contain a cycloplegic agent, a surfactant, a viscosity enhancer, an osmolarity modifier and a preservative.
    Type: Application
    Filed: October 10, 2018
    Publication date: February 7, 2019
    Inventor: Gerald Horn
  • CANCER THERAPY
    Publication number: 20190038610
    Abstract: A method of treating haematological cancer with a therapy comprising a DHODH inhibitor. Also provided is a combination therapy comprising a pan-HER inhibitor and a DHODH inhibitor for treating a haematological cancer.
    Type: Application
    Filed: October 8, 2018
    Publication date: February 7, 2019
    Applicant: Aslan Pharmaceuticals Pte. Ltd.
    Inventors: Bertil Lindmark, Ann Gee Lisa Ooi
  • Novel CYP34A-Specific Inhibitors and Methods of Using Same
    Publication number: 20190038611
    Abstract: The present invention includes novel compositions inhibiting CYP3A4. The present invention further includes a novel method of inhibiting CYP3A4 in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of the invention. In one embodiment, the subject is further administered at least one additional therapeutic agent.
    Type: Application
    Filed: September 9, 2016
    Publication date: February 7, 2019
    Inventor: Irina Sevrioukova
  • N3,N6-BIS(2-(5-METHOXY-1H-INDOLE-3-YL)ETHYL)-2,6-DIMETHYL-4-(2-NITROPHENYL)PYRIDINE-3,5-DICARBOXAMIDE AND USE THEREOF IN THE FIELD OF NEUROTOXICITY
    Publication number: 20190038612
    Abstract: The invention relates to a molecule enabling removal of neurotoxicity observed in neuron cells due to various reasons.
    Type: Application
    Filed: January 26, 2017
    Publication date: February 7, 2019
    Inventors: Ahmet HACIMUFTUOGLU, Orhan ATES, Nurullah SARACOGLU, Ali TAGHIZADEHGHALEHJOUGHI, Farrokh LAFZI
  • COMBINATION THERAPY
    Publication number: 20190038613
    Abstract: The present invention provides a method of treating a cognitive or neurodegenerative disease, comprising administering to a patient in need of such treatment an effective amount of (1r, 1?R,4R)-4-methoxy-5?-methyl-6?-[5-(prop-1-yn-1-yl)pyridin-3-yl]-3?H-dispiro[cyclohexane-1,2?-indene-1?,2?-imidazol]-4?-amine, or a pharmaceutically acceptable salt thereof (including the camsylate salt thereof); in combination with an effective amount of an anti-N3pGlu Abeta antibody.
    Type: Application
    Filed: March 10, 2017
    Publication date: February 7, 2019
    Inventors: Ronald Bradley DeMattos, Patrick Cornelius May, John Randall Sims, II
  • PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREFOR
    Publication number: 20190038614
    Abstract: The present invention provides an oral pharmaceutical composition and a usage thereof, comprising a pharmaceutically acceptable acidic medicinal auxiliary material whose surface is modified and dabigatran etexilate or pharmaceutically acceptable salts or aquo-complexes thereof. The present invention further provides a surface modification method for a medicinal auxiliary material.
    Type: Application
    Filed: October 10, 2018
    Publication date: February 7, 2019
    Inventors: Zeren WANG, Yulan ZHAO, Lijiang WANG, Xiao ZHANG, Jun XU, Shunqin CHEN, Meili SUN, Guisheng JIANG
  • PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF
    Publication number: 20190038615
    Abstract: The present invention relates to pharmaceutical compositions comprising a compound of Formula I in combination with one or both of a Compound of Formula II and/or a Compound of Formula III. The invention also relates to solid forms and to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis.
    Type: Application
    Filed: February 19, 2018
    Publication date: February 7, 2019
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Fredrick F. Van Goor, Rossitza Gueorguieva Alargova, Tim Edward Alcacio, Sneha G. Arekar, Steven C. Johnston, Irina Nicolaevna Kadiyala, Ali Keshavarz-Shokri, Mariusz Krawiec, Elaine Chungmin Lee, Ales Medek, Praveen Mudunuri, Mark Jeffrey Sullivan, Noreen Tasneem Zaman, Beili Zhang, Yuegang Zhang, Gregor Zlokarnik
  • ANTI-NEUTROPHIL ACTIVITY ON INNATE IMMUNE RESPONSE
    Publication number: 20190038616
    Abstract: Disclosed are compositions, medical devices and methods for ameliorating sterile injury due object use in a subject in need thereof. More particularly, the present disclosure relates to compositions including N-Acetylcysteine and an aminoquinoline. The present disclosure also relates to compositions including an endonuclease and an aminoquinoline. The present disclosure also relates to medical devices including a coating comprising N-Acetyl-cysteine, an aminoquinoline, an endonuclease, and combinations thereof.
    Type: Application
    Filed: January 23, 2017
    Publication date: February 7, 2019
    Inventor: Carlos A. PUYO
  • METHODS OF TREATING CANCER WITH FARNESYLTRANSFERASE INHIBITORS
    Publication number: 20190038617
    Abstract: The present invention relates to the field of cancer therapy. Specifically, provided are methods of treating cancer in a subject having clinical signs of bone marrow homing of myeloid cells, including neutropenia, isolated neutropenia, a low percentage of peripheral blood blasts with or without a high percentage of bone marrow blasts, and/or a low ratio of peripheral blood blasts to bone marrow blasts, with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on hematological characteristics indicating bone marrow homing of myeloid cells.
    Type: Application
    Filed: November 21, 2017
    Publication date: February 7, 2019
    Inventor: Antonio GUALBERTO
  • MORPHINAN COMPOUNDS
    Publication number: 20190038618
    Abstract: This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a ?1 receptor agonist that also has NMDA antagonist activity.
    Type: Application
    Filed: July 16, 2018
    Publication date: February 7, 2019
    Inventors: Philip B. Graham, I. Robert Silverman
  • PRODUCT AND METHOD FOR TREATING DIARRHEA
    Publication number: 20190038619
    Abstract: A method of treating diarrhea in a patient includes administering an H1 receptor antagonist and an H2 receptor antagonist to the patient.
    Type: Application
    Filed: July 6, 2018
    Publication date: February 7, 2019
    Inventor: Reed B. Hogan
  • DELTA OPIOID AGONIST MU OPIOID ANTAGONIST COMPOSITIONS AND METHODS FOR TREATING PARKINSONS DISEASE
    Publication number: 20190038620
    Abstract: The present invention provides for compositions and methods for the treatment of Parkinson's disease comprising a compound of formula (i): or a pharmaceutically effective salt or ester thereof alone or in combination with L-DOPA to provide a synergistic effect, thereby providing methods of (1) treating patients with Parkinson's Disease for whom L-DOPA is no longer effective, (2) treating patients with Parkinson's Disease who developed dyskinesia due to L-DOPA, (3) treating patients with Parkinson's Disease who have are receiving deep brain stimulation and (4) treating patients with Parkinson's Disease whose symptoms interfere with activities of daily living.
    Type: Application
    Filed: March 30, 2017
    Publication date: February 7, 2019
    Inventors: EBRAHIM VERSI, BRUCE REIDENBERG
  • POSACONAZOLE DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USE THEREOF
    Publication number: 20190038621
    Abstract: The present disclosure provides a posaconazole derivative, a pharmaceutical composition and use thereof, which specifically include a compound represented by the following formula (I), a racemate, stereoisomer, tautomer, oxynitride, or a pharmaceutically acceptable salt thereof: The compounds of the present disclosure have strong antifungal activity, high safety, and good water solubility, without the need for the addition of a cosolvent (such as hydroxypropyl-?-cyclodextrin, sulfobutyl ether-?-cyclodextrin, and the like) with potential safety risks. Furthermore, the formulation process of the compound could have less difficulty and less cost, and therefore can be used to prepare improved antifungal drugs.
    Type: Application
    Filed: January 26, 2017
    Publication date: February 7, 2019
    Inventors: Jun LOU, Penggao YU, Li LIU, Hongwei TANG, Anxiao ZHENG, Yongkai CHEN, Chaodong WANG
  • NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES
    Publication number: 20190038622
    Abstract: A compound having formula IA is useful for treating a neurodegenerative disease: or a pharmaceutically acceptable salt or ester thereof, where R0, R1, R2, R7, R8 are delineated substituents; A1 is a C6-12 aryl group, C5-12 heteroaryl group, substituted 3-hydroxypyridin-4(1H)-one, with i hydrogen atoms replaced with R7 and j hydrogen atoms replaced with R8; p is an integer from 1 to 6; X1, Y1 are each independently CH or N; M is absent or a divalent linking moiety in which Z is repeated m times; m is an integer from 0 to 5; i, j are each independently 0, 1, 2, or 3; and o is 0, 1, 2, 3, or 4.
    Type: Application
    Filed: October 8, 2018
    Publication date: February 7, 2019
    Inventor: Aloke K. Dutta
  • THERAPEUTIC REGIMENS FOR TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
    Publication number: 20190038623
    Abstract: Provided herein are methods for treating a subject with PNH comprising administering to a subject a therapeutically effective amount of complement component C5 (C5) inhibitor, complement component C3 (C3) inhibitor, or complement factor B (CFB) inhibitor in combination with a therapeutically effective amount of small molecule complement factor D (CFD) inhibitor of Formula I or Formula II, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 2, 2018
    Publication date: February 7, 2019
    Applicant: Achillion Pharmaceuticals, Inc.
    Inventors: Mingjun Huang, Dharaben Patel, Steven D. Podos
  • USE OF ABELSON TYROSINE KINASE INHIBITOR IN TREATMENT OF MULTIPLE SYSTEM ATROPHY
    Publication number: 20190038624
    Abstract: The present disclosure relates to a method for treating or alleviating a symptom of MSA, comprising administering a therapeutically effective amount of an abelson (Abl) tyrosine kinase inhibitor to a subject in need thereof.
    Type: Application
    Filed: August 3, 2018
    Publication date: February 7, 2019
    Inventors: Daniel Dung Truong, Trang Nguyen Ngoc Vo, Cong Huu Nguyen
  • INHIBITORS AND THEIR USES
    Publication number: 20190038625
    Abstract: The invention relates to inhibitors of CDK12 (cyclin-dependent kinase 12), and there use in the treatment or prevention of a disorder in a subject caused by the generation of repeat expansion transcripts.
    Type: Application
    Filed: March 23, 2017
    Publication date: February 7, 2019
    Inventors: Christopher James Hayes, John David Brook, Ami Ketley
  • HEAT SHOCK PROTEIN BINDING COMPOUNDS, COMPOSITIONS, AND METHODS FOR MAKING AND USING SAME
    Publication number: 20190038626
    Abstract: The present subject matter relates to a compound represented by the general formula (I) or (I?) or a pharmacologically acceptable salt thereof; pharmaceutical compositions containing at least one of these compounds; methods of making at least one of these compounds; methods of using at least one of these compounds for treating and/or preventing various cancers and/or proliferation disorders; methods of using at least one of these compounds for monitoring the effectiveness of an anticancer therapy against various cancers. In one embodiment, the subject matter relates to compounds that bind with a level of specificity to heat shock protein 70 (Hsp70). In another embodiment, the subject matter relates to compounds that bind with a level of specificity to inhibit both heat shock protein 70 (Hsp70) and heat shock cognate protein 70 (Hsc70).
    Type: Application
    Filed: July 17, 2018
    Publication date: February 7, 2019
    Inventors: Gabriela Chiosis, Tony Taldone, Anna Rodina, Pallav Patel, Yanlong Kang
  • METHANOCARBA DERIVATIVES OF PSEUDORIBOSE THAT INHIBIT ADENOSINE KINASE
    Publication number: 20190038627
    Abstract: Adenosine kinase inhibitors, including pharmaceutical compositions containing the adenosine kinase inhibitors, and their use for preventing epilepsy and its progression in patients. The adenosine kinase inhibitors have the formula: where the moieties J and K, considered in combination, are —CH2—, or K and L, considered in combination, are —CH2—. The R1 moiety can be —NH2, C1-C6 alkyl, C1-C6 alkoxy, or C1-C6 hydroxyalkyl. The R2 and R3 moieties are each independently C1-C6 alkyl. The R4 moiety is hydrogen or C1-C6 alkyl. The R5 and R6 moieties are each independently C6-C12 aryl, C3-C8 cycloalkyl, or C3-C8 heteroaryl, that is optionally further substituted.
    Type: Application
    Filed: July 9, 2018
    Publication date: February 7, 2019
    Applicants: Legacy Emanuel Hospital & Health Center, The United States of America, as represented by the Secretary, Department of Health and Human Serv
    Inventors: Kenneth Alan Jacobson, Detlev Boison, Kiran Shambhu Toti
  • USE OF INHIBITORS OF THE ACTIVITY OR FUNCTION OF PI3K FOR THE TREATMENT OF PRIMARY SJOGREN'S SYNDROME
    Publication number: 20190038628
    Abstract: The invention relates to the use of 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one or pharmaceutically acceptable salts thereof for the treatment of primary Sjögren's Syndrome.
    Type: Application
    Filed: February 10, 2017
    Publication date: February 7, 2019
    Inventors: Bruno BIETH, Christoph BURKHART, Andreas CHRIST, Stefan DE BUCK, Christoph KALIS, Sam LINDGREN
  • CONCENTRATED METHOTREXATE SOLUTIONS
    Publication number: 20190038629
    Abstract: Concentrated methotrexate solutions are described which are suitable for the use of an active substance in the production of a parenterally administered medicament for the treatment of inflammatory autoimmune diseases. The methotrexate is added to a pharmaceutically acceptable solvent at a concentration of more than 25 mg/ml.
    Type: Application
    Filed: October 5, 2018
    Publication date: February 7, 2019
    Applicant: MEDAC GESELLSCHAFT FUER KLINISCHE SPEZIALPRAEPARARATE MBH
    Inventor: Heiner WILL
  • USE OF ADENOSINE RECEPTOR SIGNALING TO REGULATE P-GP FUNCTION
    Publication number: 20190038630
    Abstract: The present invention relates to a method of inhibiting p-glycoprotein (P-gp) expression in a cell. The method involves contacting a cell expressing P-gp with a composition comprising an effective amount of an A2A adenosine receptor (A2A AR) agonist to inhibit P-gp expression in the cell. Methods of enhancing the bioavailability of a chemotherapeutic in a subject having multi-drug resistant (MDR) cancer and methods of increasing P-gp-mediated efflux in a cell are also disclosed.
    Type: Application
    Filed: February 3, 2017
    Publication date: February 7, 2019
    Inventor: Margaret BYNOE
  • 6-AMINO-PURIN-8-ONE COMPOUNDS
    Publication number: 20190038631
    Abstract: Compounds of formula (I): wherein R1 is C1-6alkylamino, C1-6alkoxy, or C3-7cycloalkyloxy; m is an integer having a value of 3 to 6; n is an integer having a value of 0 to 4; and salts thereof are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions for example allergic rhinitis and asthma, the treatment of infectious diseases and cancer, and may also be useful as vaccine adjuvants.
    Type: Application
    Filed: October 1, 2018
    Publication date: February 7, 2019
    Inventors: Keith BIGGADIKE, Diane Mary Coe, Xiao Qing LEWELL, Charlotte Jane MITCHELL, Stephen Allan SMITH, Naimisha TRIVEDI
  • COPANLISIB BIOMARKERS
    Publication number: 20190038632
    Abstract: This invention provides biomarkers based on the gene expression profiling which can discriminate between patients who response to and/or with longer progression free survival and patients who do not response to and/or with shorter progression free survival from copanlisib treatment in lymphoma including indolent and aggressive NHLs and CLLs. The present invention relates to the use of genes from the BCR, PI3K, NFkB, IL6, inflammation and stromal processes as predictive biomarkers for various human cancers including but not limited to NHLs.
    Type: Application
    Filed: January 30, 2017
    Publication date: February 7, 2019
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Li LIU, Carol PENA, Jie CHENG, Karl KÖCHERT
  • METHODS OF TREATING CANCER
    Publication number: 20190038633
    Abstract: The disclosure relates to a method for treating cancer comprising administering a therapeutically effective amount of an EZH2 inhibitor to a subject in need thereof, wherein the cancer is characterized by at least one cancer cell originating from a stem cell, a progenitor cell, or an immature cell and wherein the at least one cancer cell comprises one or more genetic lesion(s) that confer(s) dependence of the cancer cell on an EZH2 function. In certain embodiments, the EZH2 inhibitor of the disclosure is tazemetostat or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 8, 2017
    Publication date: February 7, 2019
    Inventors: Jesse SMITH, Heike KEILHACK, Scott RIBICH
  • PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS
    Publication number: 20190038634
    Abstract: The present invention relates to compounds useful as pharmaceutical intermediates, to processes for preparing the intermediates, to intermediates used in the processes, and to the use of the intermediates in the preparation of pharmaceuticals. In particular, the present invention concerns enantiomerically pure optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives represented by formula (IA) and (IB), processes for preparing the alcohol derivatives and their use in preparing pharmaceuticals.
    Type: Application
    Filed: October 10, 2018
    Publication date: February 7, 2019
    Inventors: Jayaraman V. Raman, Swaroop K. Vakkalanka
  • SOLID DOSAGE FORMULATIONS OF AN OREXIN RECEPTOR ANTAGONIST
    Publication number: 20190038635
    Abstract: The present invention is directed to a pharmaceutical composition comprising the compound suvorexant, or a pharmaceutically acceptable salt thereof, a concentration-enhancing polymer, and optionally a pharmaceutically acceptable surfactant.
    Type: Application
    Filed: August 9, 2018
    Publication date: February 7, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Paul A. Harmon, Narayan Variankaval
  • Use of Medications with Neuroprotective Properties to Prevent or Reduce the Risk of Ischemia-Reperfusion Injury in a Subject
    Publication number: 20190038636
    Abstract: Provided are methods for treatment and prevention of ischemia-reperfusion injury and chronic intermittent hypoxia related injury through administering a neuroprotective compound. A subject benefiting from the method of the invention may be prescribed or undergoing anti-VEGF treatment, for example an IVAV treatment regimen, or may be diagnosed with a disorder such as sleep apnea.
    Type: Application
    Filed: October 8, 2018
    Publication date: February 7, 2019
    Inventor: Tamara Vrabec
  • Use of Hydroxyprogesterone Derivatives for Enhanced Health and Physical Performance II
    Publication number: 20190038637
    Abstract: A method for the use of derivatives of hydroxyprogesterone (17-alpha-hydroxypregn-4-ene-3,20-dione) to enhance health and physical performance in humans and more particularly to the use of hydroxyprogesterone derivatives for restoring renal hormonal balance, decreasing body weight, reducing adipose tissue, increasing endurance, promoting skeletal muscle growth, boosting androgen levels, inhibiting aromatase, and increasing cognitive function.
    Type: Application
    Filed: August 5, 2017
    Publication date: February 7, 2019
    Inventor: Eric Marchewitz
  • FORMULATIONS OF DEOXYCHOLIC ACID AND SALTS THEREOF
    Publication number: 20190038638
    Abstract: The present application is directed to an aqueous pharmaceutical formulation comprising less than about 5% w/v sodium deoxycholate maintained at a pH sufficient to substantially inhibit precipitation of the sodium deoxycholate. Also disclosed herein, are methods for inhibiting precipitation of sodium deoxycholate in an aqueous solution comprising less than about 5% w/v of sodium deoxycholate, said method comprising maintaining pH of the solution of from at least about 8.0 to about 8.5.
    Type: Application
    Filed: August 14, 2018
    Publication date: February 7, 2019
    Applicant: Kythera Biopharmaceuticals, Inc.
    Inventors: Robert Emil HODGE, Jeffrey Douglas WEBSTER
  • METHODS OF TREATING EPILEPSY OR STATUS EPILEPTICUS
    Publication number: 20190038639
    Abstract: Described herein are methods of treating epilepsy or status epilepticus, e.g., convulsive status epilepticus, e.g., early status epilepticus, established status epilepticus, refractory status epilepticus, super-refractory status epilepticus, e.g., super-refractory generalized status epilepticus; non-convulsive status epilepticus, e.g., generalized status epilepticus, complex partial status epilepticus; generalized periodic epileptiform discharges; periodic lateralized epileptiform discharges; a seizure, e.g., acute repetitive seizures, cluster seizures, the method comprising administering to the subject a neuroactive steroid.
    Type: Application
    Filed: March 29, 2018
    Publication date: February 7, 2019
    Inventors: Kiran Reddy, Stephen J. Kanes
  • COMPOSITION, FORMULATIONS AND METHODS OF MAKING AND USING BOTANICALS AND NATURAL COMPOUNDS FOR THE PROMOTION OF HEALTHY BRAIN AGING
    Publication number: 20190038640
    Abstract: The present disclosure provides compositions and formulations comprising botanicals and natural compounds for the promotion of healthy brain aging in adults, especially adult women, and for prevention of age associated neurodegenerative changes resulting in cognitive, memory and executive dysfunction including modulation of the age related predisposition to mild cognitive impairment, Alzheimer's disease, hormonal and other dementia related conditions. The present disclosure also provides methods of using the compositions and formulations in treating and preventing neurodegenerative changes resulting in cognitive, memory and executive dysfunction.
    Type: Application
    Filed: January 16, 2018
    Publication date: February 7, 2019
    Inventor: Morris NOTELOVITZ
  • COMBINATION THERAPY FOR CASTRATION-RESISTANT PROSTRATE CANCER
    Publication number: 20190038641
    Abstract: Certain embodiments of the current disclosure are directed to a combined vitamin D (calcitriol or analog thereof) and androgen therapy that reduces the growth of mCRPC in humans. In certain aspects a new combined vitamin D and androgen medication formulation is described that controls advanced prostate cancer. Calcitriol, calcitriol analogs, and androgens are referred to herein as therapeutic agents or agents.
    Type: Application
    Filed: February 3, 2017
    Publication date: February 7, 2019
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Bandana CHATTERJEE, Sulgi PARK, Chung S. SONG
  • TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTS
    Publication number: 20190038642
    Abstract: Provided herein are compositions, systems, and methods for treating a disease, such as kidney and/or cardiovascular disease, with an agent that reduces the production of trimethylamine (TMA) or trimethylamine-n-oxide (TMAO) in a subject. In certain embodiments, the agent is: i) 3,3-dimethyl-1-butanol (DMB) or a DMB derivative or related compound, ii) acetylsalicylic acid or derivative thereof (e.g., with an enteric coating for delivery to the colon and/or cecum); iii) a flavin monooxygenase 3 (FMO3) inhibitor; iv) a gut TMA lyase inhibitor; v) an antibiotic or antimicrobial; vi) a probiotic or prebiotic; vii) an antiplatelet agent; or viii) a TMA and/or TMAO sequestering agent.
    Type: Application
    Filed: October 12, 2018
    Publication date: February 7, 2019
    Inventor: Stanley L. Hazen
  • Hydrogen Sulfide (H2S) Releasing Donor Compound For Dermal Wound Regeneration
    Publication number: 20190038643
    Abstract: A dressing for wound healing is provided, wherein the dressing includes a hydrogen sulfide (H2S) donor compound. The dressing facilitates the delivery of H2S to a wound site in a controlled manner, which results in an improved wound healing process by stimulating angiogenesis and anti-inflammatory action. In some embodiments, the wound dressing can include an electrospun nanofiber dressing, a sponge dressing, or a hydrogel dressing.
    Type: Application
    Filed: August 1, 2017
    Publication date: February 7, 2019
    Inventor: Qian Wang
  • PREPARATION FOR NASAL-NASOPHARYNGEAL TREATMENT
    Publication number: 20190038644
    Abstract: Medicinal compositions or preparations or drugs for the treatment of disorders of the respiratory system such as the nasal-nasopharyngeal area. The preparation may include a carrier, between about 0.8% and 59% by weight/volume of a medicament selected from the group consisting of sugar monomers of the aldohexose series of carbohydrates; and a pharmaceutically effective amount of an antimicrobial preservative.
    Type: Application
    Filed: August 5, 2018
    Publication date: February 7, 2019
    Inventors: Sheralee McDonald GREVES, Wendy Sharon GENN, Dimitri John TERPIZIS, Costas Lambros TERPIZIS
  • AGENT FOR OVERCOMING IMMUNOSUPPRESSION AND USE THEREOF
    Publication number: 20190038645
    Abstract: To provide an agent for overcoming immunosuppression which can overcome immunosuppression by regulatory T cells. An agent for overcoming immunosuppression and an inhibitor of FOXP3 function containing an anthracycline antibiotic as an active ingredient.
    Type: Application
    Filed: February 15, 2017
    Publication date: February 7, 2019
    Applicants: GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION, KABUSHIKI KAISHA YAKULT HONSHA
    Inventors: Akira ASAI, Naohisa OGO, Daisuke MURAOKA, Hiroshi SHIKU, Naozumi HARADA
  • METHODS, AGENTS, AND DEVICES FOR LOCAL NEUROMODULATION OF AUTONOMIC NERVES
    Publication number: 20190038646
    Abstract: Methods, agents, and devices to treat medical conditions through local chemical neuromodulation of the autonomic nervous system are described. Drug formulations may be injected at or near ganglia, nerve plexi, ganglionated plexi, and nerves to treat different diseases. Target sites for the treatment of cardiac and other disease conditions may include extrinsic stellate (cervicothoracic) and cervical ganglia of the sympathetic chain, and intrinsic cardiac nerves and ganglionated plexi innervating the myocardium.
    Type: Application
    Filed: February 9, 2017
    Publication date: February 7, 2019
    Inventors: Corinne Bright, Kondapavulur T. Venkateswara-Rao, Emily Stein
  • METHOD OF TREATING HEART FAILURE
    Publication number: 20190038647
    Abstract: Disclosed herein is a method for treating heart failure in a subject in need thereof. The method includes administering a therapeutically effective amount of nicotinamide riboside to the subject. The heart failure may be associated with iron deficiency. The method may also include administering iron to the subject.
    Type: Application
    Filed: February 10, 2016
    Publication date: February 7, 2019
    Inventors: Nancy C. Andrews, Wenjing Xu, Anthony A. Sauve
  • MATERIALS AND METHODS FOR SUPPRESSING AND/OR TREATING BACTERIAL INFECTIONS AND RELATED SYMPTOMS
    Publication number: 20190038648
    Abstract: Various aspects and embodiments disclosed herein relate generally to the modelling, treatment, reducing resistence to the treatment, prevention, and diagnosis of diseases/symptoms induced by infectious bacteria. Embodiments include methods of treating a bacterial infection, comprising the steps of: providing to a patient diagnosed with staphylococcal infection at least one therapeutically effective dose of a compound having an anti-virulence effect.
    Type: Application
    Filed: August 3, 2018
    Publication date: February 7, 2019
    Inventors: Taeok Bae, WonSik Yeo, Hyunyoung Jeong
  • MEDICAMENT FOR USE IN TREATING DIABETES
    Publication number: 20190038649
    Abstract: A medicament for treating diabetes and complications thereof, the medicament being a glycoprotein, or a mixture of a polysaccharide and a protein, or a polypeptide, or a protein.
    Type: Application
    Filed: January 20, 2017
    Publication date: February 7, 2019
    Applicant: Shandong Zhonghai Pharmaceutical CO. LTD
    Inventors: Baozhen XU, Qian CHENG, Long CHENG
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF ATHEROSCLEROSIS AND HEPATOSTEATOSIS AND OTHER DISEASES
    Publication number: 20190038650
    Abstract: The present disclosure provides compositions comprising trehalose, and optionally a trehalase inhibitor, for the treatment of atherosclerosis and liver steatosis.
    Type: Application
    Filed: February 1, 2017
    Publication date: February 7, 2019
    Inventors: Babak Razani, Abhinav Diwan
  • USE OF FLORIDOSIDE OR ISETHIONIC ACID TO POTENTIATE ANTIMICROBIAL ACTIVITY OF ANTIBIOTICS
    Publication number: 20190038651
    Abstract: The present disclosure provides: floridoside or isethionic acid for use as an antibiotic potentiator; floridoside or isethionic acid in a combination therapy with an antibiotic compound; as well as methods of potentiating the antibiotic activity of an antibiotic compound, where the method comprises administering floridoside or isethionic acid to an animal or plant.
    Type: Application
    Filed: January 27, 2017
    Publication date: February 7, 2019
    Inventors: Balakrishnan PRITHIVIRAJ, Garima KULSHRESTHA
  • EFFECTS OF LGM2605 ON A PRIMATE MODEL OF ASTHMA
    Publication number: 20190038652
    Abstract: The invention provides compositions and methods for treating asthma in a subject in need thereof comprising administering chemically synthesized secoisolaricirecinol diglucoside (SDG), and in particular, a racemic mixture of the SDG (LGM2605), stereoisomers thereof, metabolites thereof, and analogs thereof. Also provided are methods for treating or preventing ozone-induced damage in a subject in need thereof.
    Type: Application
    Filed: October 5, 2018
    Publication date: February 7, 2019
    Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventor: Melpo CHRISTOFIDOU-SOLOMIDOU
  • COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY DISEASES
    Publication number: 20190038653
    Abstract: Described herein are compounds and pharmaceutical compositions useful for treating inflammatory diseases.
    Type: Application
    Filed: February 26, 2018
    Publication date: February 7, 2019
    Inventors: Prabhavathi FERNANDES, David Eugene PEREIRA
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20190038654
    Abstract: The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.
    Type: Application
    Filed: April 4, 2018
    Publication date: February 7, 2019
    Inventors: Uli Christian BROEDL, Odd-Erik JOHANSEN, Gabriel Woojai KIM, Eric Williams MAYOUX, Afshin SALSALI, Nima SOLEYMANLOU, Maximilian von EYNATTEN, Hans-Juergen WOERLE, David Z.I. CHERNEY, Bruce A. PERKINS, Andreas DAIBER, Thomas MUENZEL
  • CHEMICALS AND METHODS TO PREVENT AND TREAT TGF-BETA MEDIATED ACTIVATION OF FIBROBLASTS TO REDUCE AND TREAT CANCER AND FIBROSIS
    Publication number: 20190038655
    Abstract: A method of treating an activated fibroblast associated disease or pre-disease condition in a mammal comprising, administering a pharmaceutical composition including a therapeutically effective amount of a first therapeutic, wherein the first therapeutic is one of an intracellular Ca2+ elevator, a YAP/TAZ inhibitor, both a intracellular Ca2+ elevator and a YAP/TAZ inhibitor, or pharmacologically acceptable salts, solvates, esters, amides, clathrates, stereoisomers, enantiomers, prodrugs or analogs thereof, or a combination thereof.
    Type: Application
    Filed: February 2, 2017
    Publication date: February 7, 2019
    Inventors: James Allen CARDELLI, Charles Albert STEPHENS, Alana Lea GRAY, David Thomas COLEMAN
  • ANTHRANILYL-ADENOSINEMONOSULFAMATE ANALOGS AND USES THEREOF
    Publication number: 20190038656
    Abstract: Provided herein are compounds of Formula (I) and pharmaceuticals acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, and prodrugs thereof. Also provided are pharmaceutical compositions, kits, and methods involving the inventive compounds for the treatment and/or of an infectious disease (e.g., bacterial infection (e.g., P. aeruginosa infection).
    Type: Application
    Filed: October 3, 2016
    Publication date: February 7, 2019
    Applicants: Memorial Slooan-Kettering Cancer Center, The General Hospital Corporation d/b/a Massachusetts General Hospital, East Carolina University
    Inventors: Derek Shieh Tan, Cheng Ji, Indrajeet Sharma, Debarshi Pratihar, James P. Coleman, Everett C. Pesci, Laurence G. Rahme
  • COMPOSITIONS AND METHODS FOR TREATING FIBROTIC DISEASE
    Publication number: 20190038657
    Abstract: The present disclosure relates to compositions and methods for treating or preventing a fibrotic disorder or disease.
    Type: Application
    Filed: May 7, 2018
    Publication date: February 7, 2019
    Inventors: James APPLEMAN, Peggy A. THOMPSON
  • HIGH DENSITY LIPOPROTEIN BINDING PROTEIN (HDLBP/VIGILIN) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20190038658
    Abstract: The invention relates to double stranded ribonucleic acid (dsRNA) agents and compositions targeting a High Density Lipoprotein Binding Protein (Hdlbp/Vigilin) gene, as well as methods of inhibiting expression of Hdlbp/Vigilin and methods of treating subjects having a disorder of lipid metabolism, such as mixed hyperlipidemia, hypertriglyceridemia or hypercholesterolemia, using such dsRNA agents and compositions.
    Type: Application
    Filed: October 17, 2018
    Publication date: February 7, 2019
    Inventors: Muthiah Manoharan, Markus Stoffel, Mehrpouya Balaghy Mobin